Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 in nAMD and DME (Phase 1/2)
CTR20212710Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in exudative macular degeneration, diabetic macular edema (DME), sponsored by Innovent Biologics. Started Nov 2021; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20212710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212710.